Denali TherapeuticsDNLI
About: Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.
Employees: 422
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
100% more funds holding in top 10
Funds holding in top 10: 1 [Q3] → 2 (+1) [Q4]
80% more call options, than puts
Call options by funds: $1.35M | Put options by funds: $750K
38% more repeat investments, than reductions
Existing positions increased: 83 | Existing positions reduced: 60
24% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 33
2% more funds holding
Funds holding: 216 [Q3] → 221 (+5) [Q4]
0.61% more ownership
Funds ownership: 88.26% [Q3] → 88.87% (+0.61%) [Q4]
29% less capital invested
Capital invested by funds: $3.68B [Q3] → $2.61B (-$1.07B) [Q4]
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
7 analyst ratings
B of A Securities Tazeen Ahmad 25% 1-year accuracy 8 / 32 met price target | 92%upside $28 | Buy Maintained | 10 Mar 2025 |
Morgan Stanley Matthew Harrison 40% 1-year accuracy 8 / 20 met price target | 126%upside $33 | Overweight Assumed | 7 Mar 2025 |
B. Riley Securities Mayank Mamtani 9% 1-year accuracy 2 / 22 met price target | 140%upside $35 | Buy Reiterated | 5 Mar 2025 |
Oppenheimer Jay Olson 19% 1-year accuracy 16 / 83 met price target | 188%upside $42 | Outperform Maintained | 3 Mar 2025 |
HC Wainwright & Co. Andrew Fein 26% 1-year accuracy 94 / 355 met price target | 496%upside $87 | Buy Maintained | 28 Feb 2025 |
Financial journalist opinion
Based on 3 articles about DNLI published over the past 30 days









